NYSE:HAE - Haemonetics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$102.47 +1.30 (+1.28 %)
(As of 05/23/2019 09:18 AM ET)
Previous Close$101.17
Today's Range$100.57 - $102.99
52-Week Range$80.24 - $117.56
Volume492,547 shs
Average Volume634,054 shs
Market Capitalization$5.23 billion
P/E Ratio42.87
Dividend YieldN/A
Beta0.85
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
CUSIP40502410
Phone781-848-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$967.58 million
Cash Flow$4.6897 per share
Book Value$13.09 per share

Profitability

Net Income$55.02 million

Miscellaneous

Employees3,136
Market Cap$5.23 billion
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable

Haemonetics (NYSE:HAE) Frequently Asked Questions

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

How will Haemonetics' stock buyback program work?

Haemonetics declared that its Board of Directors has approved a stock repurchase plan on Tuesday, February 6th 2018, which permits the company to buyback $260,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company's management believes its stock is undervalued.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) posted its earnings results on Tuesday, May, 7th. The medical instruments supplier reported $0.61 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.55 by $0.06. The medical instruments supplier had revenue of $249.30 million for the quarter, compared to analyst estimates of $250.62 million. Haemonetics had a net margin of 5.69% and a return on equity of 18.88%. Haemonetics's quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.43 EPS. View Haemonetics' Earnings History.

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Haemonetics.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics updated its FY20 earnings guidance on Tuesday, May, 7th. The company provided EPS guidance of $2.80-3.00 for the period, compared to the Thomson Reuters consensus estimate of $2.89. The company issued revenue guidance of +5-7% to ~$1.02-1.04 billion, compared to the consensus revenue estimate of $1.04 billion.Haemonetics also updated its FY 2020 guidance to $2.80-3.00 EPS.

What price target have analysts set for HAE?

4 equities research analysts have issued 1 year price objectives for Haemonetics' shares. Their forecasts range from $110.00 to $125.00. On average, they anticipate Haemonetics' share price to reach $117.75 in the next twelve months. This suggests a possible upside of 14.9% from the stock's current price. View Analyst Price Targets for Haemonetics.

What is the consensus analysts' recommendation for Haemonetics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics.

What are Wall Street analysts saying about Haemonetics stock?

Here are some recent quotes from research analysts about Haemonetics stock:
  • 1. According to Zacks Investment Research, "Haemonetics registered encouraging growth at the Plasma and Hospitals segments in its third-quarter, fiscal 2019, However, sluggish Blood Center business moderated overall growth in the reporting cycle. Moreover, tough competitive environment also weighed on the stock. On a positive note, Haemonetics promising third-quarter fiscal 2019 result benefitted from complexity reduction and investments, along with strength in market demand and success from early launches, helped the company put up an impressive performance. Continued momentum in business generation and geographical expansion contributed to results. We are upbeat about the company’s steady progress, with the launch of NexSys PCS devices and NexLynk DMS donor management software. Over the past year, Haemonetics has been outperforming its industry." (4/9/2019)
  • 2. Barrington Research analysts commented, "We believe that a full transition of the company’s 20,000 base could add $2 or more per plasma donation (i.e. $70 million plus)." (10/5/2018)

Has Haemonetics been receiving favorable news coverage?

Press coverage about HAE stock has been trending very negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Haemonetics earned a daily sentiment score of -3.8 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.

Who are some of Haemonetics' key competitors?

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include Endologix (ELGX), Align Technology (ALGN), Zoetis (ZTS), Apache (APA), Chipotle Mexican Grill (CMG), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), CA (CA), NVIDIA (NVDA) and Nexstar Media Group (NXST).

Who are Haemonetics' key executives?

Haemonetics' management team includes the folowing people:
  • Mr. Christopher Simon, CEO, Pres & Director (Age 55)
  • Mr. William P. Burke, CFO & Exec. VP
  • Ms. Michelle L. Basil, Exec. VP, Gen. Counsel & Sec.
  • Ms. Jacqueline D. Scanlan, Sr. VP of Global HR
  • Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 42)

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.52%), Wellington Management Group LLP (11.64%), Renaissance Technologies LLC (4.66%), Jackson Square Partners LLC (3.25%), Neuberger Berman Group LLC (3.19%) and AQR Capital Management LLC (2.12%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Susan Bartlett Foote, Willaim P Burke and William P Mr Burke. View Institutional Ownership Trends for Haemonetics.

Which institutional investors are selling Haemonetics stock?

HAE stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Dimensional Fund Advisors LP, MERIAN GLOBAL INVESTORS UK Ltd, Federated Investors Inc. PA, American Capital Management Inc., Parametric Portfolio Associates LLC, JPMorgan Chase & Co. and Macquarie Group Ltd.. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman and William P Mr Burke. View Insider Buying and Selling for Haemonetics.

Which institutional investors are buying Haemonetics stock?

HAE stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., AQR Capital Management LLC, Neuberger Berman Group LLC, Jackson Square Partners LLC, Morgan Stanley, Eminence Capital LP and Ellis Investment Partners LLC. View Insider Buying and Selling for Haemonetics.

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $102.47.

How big of a company is Haemonetics?

Haemonetics has a market capitalization of $5.23 billion and generates $967.58 million in revenue each year. The medical instruments supplier earns $55.02 million in net income (profit) each year or $2.39 on an earnings per share basis. Haemonetics employs 3,136 workers across the globe.

What is Haemonetics' official website?

The official website for Haemonetics is http://www.haemonetics.com/.

How can I contact Haemonetics?

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]


MarketBeat Community Rating for Haemonetics (NYSE HAE)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  347 (Vote Underperform)
Total Votes:  605
MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe HAE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HAE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/23/2019 by MarketBeat.com Staff

Featured Article: Inflation

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel